Many drugs are believed to cause acute pancreatitis.
In this study, researchers compared the risks for drugs for which reports of pancreatitis were either common or uncommon.
The team used the UK General Practitioner Research Database to compare data.
Their findings are published in the April issue of Alimentary Pharmacology and Therapeutics.
They examined drug prescriptions in 3673 patients with acute pancreatitis, as well as in matched controls.
|Recent users of mesalazine showed a markedly increased risk.|
|Alimentary Pharmacology and Therapeutics|
The researchers calculated odds ratios for recent (1 to 90 days before the episode), past (91 to 360 days before the episode) or continuing (prescription in both periods) use.
The team found that odds ratios were markedly increased for recent antisecretory use in non-ulcer patients only. For all H2-antagonists odds were 12.4, and for all proton pump antagonists 9.3.
They also identified a smaller increase for past use (3.1 and 3.5, respectively) and continuing use (2.6 and 3.7, respectively) use in patients without ulcer.
In addition, recent users of mesalazine showed a markedly increased risk (9.0), with smaller increases in past and continuing users (4.5 and 2.5, respectively).
Odds ratios for other drugs, suspect or not, were modestly increased, irrespective of whether the use was recent, past or continuing.
Furthermore, the presence of gall-stones was not associated with a modified risk.
Dr Lancashire’s team concluded, “Mesalazine, azathioprine and antisecretory drugs in non-ulcer subjects may increase the risk of pancreatitis”.
However, “Warnings of drug-induced pancreatitis are generally not accompanied by increased population risks”.